MOSPD2–CD63–Integrin β2 Targeting for Inflammatory Cell Migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and disorders, as well as cancer and cancer metastasis, are limited by the redundancy of chemokine and chemokine receptor targets, and there is a need for new therapeutic approaches targeting specific molecular combinations.
Innovation Solution
Inhibiting or promoting the interaction of Motile Sperm Domain Containing Protein 2 (MOSPD2) with CD63 and/or integrin β2 to modulate the migration and adhesion of inflammatory cells, using agents such as antibodies, RNAi, or gene editing systems to target these interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemokine and chemokine receptor antagonists are used to inhibit inflammatory cell migration, then inflammatory cell migration is suppressed, but therapeutic effectiveness is reduced due to target redundancy and disease heterogeneity
Solution Approach 1:
The patent segments the inflammatory cell migration process into multiple distinct molecular interaction steps: (1) chemokine receptor-mediated initial migration, (2) MOSPD2-CD63 interaction-mediated adhesion, and (3) integrin β2 involvement in firm adhesion. By targeting specific segments (MOSPD2-CD63 interaction) rather than the entire migration pathway through chemokine receptors, the invention achieves more reliable therapeutic effectiveness while avoiding the redundancy problem of chemokine pathway targets.
Solution Approach 2:
The patent applies local quality by focusing on specific molecular interactions (MOSPD2-CD63, MOSPD2-integrin β2, CD63-integrin β2) within the broader inflammatory cell migration process. Instead of using broad-spectrum chemokine antagonists that must overcome target redundancy across multiple chemokine receptors, the invention targets the local quality of specific protein-protein interactions that are critical for the adhesion phase of migration, thereby achieving more precise and effective inhibition.
2Adaptability or versatility
If broad-spectrum anti-inflammatory agents are used to treat multiple inflammatory pathways, then coverage of heterogeneous diseases is improved, but specificity of action is reduced leading to off-target effects
Solution Approach 1:
The patent segments the complex inflammatory response into distinct molecular interaction modules, focusing on the MOSPD2-CD63-integrin β2 interaction network. This segmentation allows the invention to maintain versatility in treating heterogeneous inflammatory diseases (by targeting a conserved interaction network) while achieving high specificity (by targeting a single molecular complex rather than broad chemokine pathways).
Solution Approach 2:
The patent uses MOSPD2 as an intermediary target that connects chemokine signaling to integrin-mediated adhesion. By targeting MOSPD2 and its interactions with CD63 and integrin β2, the invention achieves precise control over inflammatory cell migration without the off-target effects associated with broad chemokine antagonists. The MOSPD2-CD63-integrin β2 complex serves as a specific molecular mediator that can be targeted across different inflammatory conditions.
Data Source
AI summary
The present disclosure relates to agents capable of modulating the interaction of Motile Sperm Domain Containing Protein 2 (MOSPD2) and CD63, MOSPD2 and integrin β2, CD63 and integrin β2, or a complex of MOSPD2, CD63 and integrin β2, compositions comprising the same, and methods of using the same. In addition, the present disclosure relates to compositions comprising an inhibitor of MOSPD2, an inhibitor of integrin β2, and/or an inhibitor of CD63, and methods of using the same.